2-Fluorofucose

2-Fluorofucose

SCHEMBL570873

C[C@@H](O)[C@H](O)[C@H](O)[C@@H](F)C=O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Fluorofucose SCHEMBL8578272 1.00
2-Fluorofucose SCHEMBL20560114 1.00
2-Fluorofucose SCHEMBL29709536 1.00
2-Fluorofucose SCHEMBL570815 0.93 TP53 (0.32)
2-Fluorofucose SCHEMBL31427535 0.93 TP53 (0.32)
SCHEMBL12561411 0.73 PTPN1 (0.36)
L-Fucose SCHEMBL466429 0.72
L-Fucose SCHEMBL11347428 0.72
L-Fucose SCHEMBL16703726 0.72
L-Fucose SCHEMBL5072536 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114386-A1 COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER OSPEDALE SAN RAFFAELE S.R.L. (IT) 2025-04-10 US claimed
EP-2282773-B2 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC (US) 2025-03-05 EP claimed
US-20230038373-A1 STABILE CONJUGATE GLYKOS BIOMEDICAL OY (FI) 2023-02-09 US claimed
US-11319526-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEAGEN INC. (US) 2022-05-03 US claimed
US-20210402002-A1 CONJUGATE GLYKOS BIOMEDICAL OY (FI) 2021-12-30 US claimed
US-20210290646-A1 COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER OSPEDALE SAN RAFFAELE S.R.L. (IT) 2021-09-23 US claimed
WO-2021123506-A1 STABILE CONJUGATE GLYKOS BIOMEDICAL OY (FI) 2021-06-24 WO claimed
US-11033561-B2 Methods of inhibition of protein fucosylation in vivo using fucose analogs SEAGEN INC. (US) 2021-06-15 US claimed
CN-112969712-A Combination of glycosylation inhibitors with CAR cell therapy for the treatment of cancer 圣拉斐尔医院有限公司 2021-06-15 CN claimed
EP-3827017-A1 COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER Ospedale San Raffaele S.r.l. (IT) 2021-06-02 EP claimed
EP-2608796-B1 INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS SEATTLE GENETICS INC (US) 2018-11-21 EP claimed
US-20180155677-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2018-06-07 US claimed
US-20170035790-A1 METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS SEATTLE GENETICS, INC. (US) 2017-02-09 US claimed
EP-2282773-B1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS INC (US) 2014-01-15 EP claimed
US-8574907-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2013-11-05 US claimed
US-20120183997-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2012-07-19 US claimed
US-8163551-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2012-04-24 US claimed
JP-2011519567-A 2011-07-14 JP claimed
EP-2282773-A2 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION Seattle Genetics, Inc. (US) 2011-02-16 EP claimed
WO-2009135181-A2 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2009-11-05 WO claimed